B-cell Acute Lymphoblastic Leukemia is an aggressive (fast-growing) type of leukemia (blood cancer) in which too many B-cell lymphoblasts (immature white blood cells) are found in the bone marrow and blood. It is the most common type of acute lymphoblastic leukemia (ALL). Also called B-cell acute lymphocytic leukemia and precursor B-lymphoblastic leukemia.
Disease: Relapsed refractory B- cell Acute Lymphoblastic Leukaemia, ALL, (2019-003462-40)
TT52CAR19 therapy for B cell acute lymphoblastic leukaemia.
CAR19+ TCRαβ- T cells.
The study treatment consists of a single administration of TT52CAR19 product. No further administration is expected. Patients will be followed for 3 years after TT52CAR19 administration.
The primary objective of the study is to evaluate the safety of TT52CAR19 cell therapy in children with relapsed or refractory B acute lymphoblastic leukaemia (B-ALL).
The secondary objective is to determine if TT52CAR19 can mediate molecular remission by day 28 and thereby allow patients to proceed to allo-SCT.Last updated: May. 14, 2020